Independent analysis puts a BCH cagrilintide lot at 96.6%, against 93.4% on the certificate
The result is unremarkable. What the report omits is not.
TheCompound Journal
Reporting on incretins, compounding & the peptide supply chain
Page 7 of 7 of this archive, newest first.
The result is unremarkable. What the report omits is not.
Our position is about documentation practice. It is not an allegation about anybody’s honesty, and we are explicit about the difference.
The Journal submitted the sample and paid for the analysis. The vendor was told in advance.